When the CME event was revived in 2016, leadership in the Division of Endocrinology and Metabolism were eager to blend the research breakthroughs occurring in the Fraternal Order of Eagles Diabetes Research Center with clinical innovations in various UI Health Care clinics in one day-long event for area clinicians interested in the latest in diabetes and obesity management.
Each year since, may have made the journey either physically or virtually to benefit from the expertise on hand at the University of Iowa. Under the direction of Yumi Imai, MD, and Marcelo Correia, MD, PhD, the Advances in Diabetes and Obesity Management presented attendees with updates in knowledge about a broad array of topics from medication to nutrition to combatting stigma around weight. In addition, a keynote from visiting lecturer Joseph Aloi, MD, focused on the effectiveness of continuous glucose monitors and insulated pumps.
Obesity and GLP-1 Medications
Leon Jons, MD
Objectives: Discuss the regulation of GLP-1 medications on eating behavior
Weight Stigma: Challenging a Harmful Norm
Kathleen Robinson, MD
Objectives: Identify and mitigate weight stigma in the healthcare context
Keynote Lecture: Integrating Technology into Diabetes Care
Joseph Aloi, MD, Professor of Internal Medicine, Chief, Section on Endocrinology and Metabolism, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Objectives: Review the data supporting use of continuous glucose sensors and automated insulin delivery in enhancing the care of persons with diabetes
Diabetic Kidney Disease: Dawn of a New Day
Diana Jalal, MD
Objectives: Review the use of SGLT2 inhibitors in the management of patients with diabetic kidney disease
Polycystic Ovary Syndrome: Effects on Metabolism as well as Fertility
Lauren Kanner, MD
Objectives: Discuss the clinical presentation and comorbidities of polycystic ovary syndrome
Improving Outcomes and Decreasing Risks: Diabetes Care in Older Adults
Amie Ogunsakin, MD
Objectives: Review risk factor for hypoglycemia in older adults and discuss mitigation strategies.
Non-alcoholic Fatty Liver Disease
Marcelo Correia, MD PhD
Objectives: Discuss the epidemiology, pathophysiology, and current treatment of non-alcoholic fatty liver disease